How to Reconstitute PT-141 (Bremelanotide): Step-by-Step Guide

What Is PT-141 and Why Reconstitution Matters

PT-141, also known by the brand name Vyleesi, is a synthetic melanocortin receptor agonist. The FDA approved bremelanotide (Vyleesi, AMAG Pharmaceuticals) on June 21, 2019, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Compounded PT-141 vials, used off-label in both men and women, arrive as lyophilized (freeze-dried) powder because the peptide is far more stable in that form than in aqueous solution.

Reconstitution converts that powder into an injectable liquid. If you skip steps, introduce contamination, or use the wrong diluent volume, the resulting concentration will be inaccurate, and your dose will be off. A 2X error in concentration means you could inadvertently receive 2 mg when you intended 1 mg, which roughly doubles the risk of nausea, the most commonly reported adverse effect in clinical trials.

How Bremelanotide Works

Bremelanotide binds to melanocortin receptors MC1R, MC3R, MC4R, and MC5R in the central nervous system [2]. Its pro-sexual effect is thought to arise primarily from MC4R agonism in the hypothalamus, distinct from PDE5 inhibitors that act on penile vasculature. That central mechanism is why PT-141 is sometimes called a "desire" compound rather than a purely mechanical one.

Regulatory Context for Compounded Vials

The FDA-approved Vyleesi product is a pre-filled, single-use auto-injector requiring no mixing. Compounded PT-141 vials fall under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which governs pharmacy compounding [3]. USP Chapter 797 sets the standards for sterile compounding, including acceptable diluents, container integrity testing, and beyond-use dating that your pharmacy must follow [4].

Supplies You Need Before You Start

Gather every item before you break the vial's seal. Stopping mid-procedure to retrieve something increases contamination risk.

Required Supplies

• PT-141 lyophilized powder vial (typically 10 mg)
• Bacteriostatic water for injection (30 mL multi-dose vial), not sterile water for injection
• Two 1 mL insulin syringes (27 to 31 gauge, 5/16 to 1/2 inch needle)
• Alcohol swabs (70% isopropyl)
• A clean, flat, well-lit surface
• Sharps disposal container

Why Bacteriostatic Water, Not Sterile Water

Bacteriostatic water (BAC water) contains 0.9% benzyl alcohol as a preservative [5]. That antimicrobial agent prevents bacterial growth across multiple punctures over weeks. Sterile water for injection (SWFI) contains no preservative. Because a reconstituted peptide vial is entered repeatedly over 28 days, SWFI would require a new single-use preparation each time, which is impractical. USP 797 permits multi-dose vials mixed with BAC water a beyond-use date of 28 days after first puncture when stored at 2 to 8 C [4].

Do not use saline (0.9% NaCl) or bacteriostatic saline as a default substitute. Peptide stability in saline can differ from BAC water depending on the molecule's charge at physiologic pH, and PT-141's manufacturer data sheets specify BAC water as the intended diluent.

Step-by-Step Reconstitution Protocol

Step 1: Hand Hygiene and Surface Prep

Wash hands for a full 20 seconds with soap and water. Dry with a clean paper towel. Wipe the work surface with a 70% isopropyl alcohol swab and let it air-dry for 30 seconds. Do not wave hands over the open area after cleaning.

Step 2: Inspect Both Vials

Check the PT-141 powder vial. The powder should be white to off-white, loosely packed, and free of visible particles or discoloration. Check the BAC water vial. It should be a clear, colorless liquid. Discard either vial if you see cloudiness, particulate matter, or cracks in the glass.

Step 3: Swab Both Vial Tops

Using separate alcohol swabs, wipe the rubber stopper of the PT-141 vial and the rubber stopper of the BAC water vial. Allow each to air-dry for 15 seconds before inserting any needle. Inserting a needle into a wet stopper can push alcohol droplets into the vial.

Step 4: Draw Bacteriostatic Water

Attach a new needle to a 1 mL insulin syringe. Insert the needle into the BAC water vial at a 45-degree angle, bevel (angled tip) up. Invert the BAC water vial and draw back the plunger slowly to pull in the desired volume. For a 10 mg PT-141 vial, draw 2.0 mL total. Because a standard 1 mL insulin syringe only holds 1 mL, you will need to fill, inject, and refill twice, or use a 3 mL syringe for the transfer.

Step 5: Inject BAC Water Into the PT-141 Vial

Insert the needle into the PT-141 vial stopper at a 45-degree angle. Direct the stream of BAC water toward the glass wall of the vial rather than directly onto the powder. This reduces foaming. Depress the plunger slowly. Never force the liquid in quickly; rapid injection denatures peptide bonds and destroys peptide structure.

Step 6: Swirl Gently, Never Shake

Once all the BAC water is in, remove the needle. Hold the vial between two fingers and roll it in a slow circle for 30 to 60 seconds. You may also tilt the vial side to side. The powder should dissolve completely within 60 to 90 seconds, producing a clear, colorless solution. If the liquid remains cloudy after 2 minutes of gentle swirling, discard the vial. Do not shake. Vigorous shaking creates air bubbles and may break disulfide bridges in the peptide chain.

Step 7: Visual Inspection

Hold the finished solution up to a light source. It must be clear and free of visible particles, fibers, or color. A very faint yellow tint is sometimes acceptable depending on the compounding batch, but confirm with your prescribing clinician before using any tinted solution.

Step 8: Label the Vial Immediately

Write the reconstitution date and the beyond-use date (28 days from today) on a label and affix it to the vial. Include the final concentration (e.g., 5 mg/mL for a 10 mg vial plus 2 mL BAC water). This prevents dosing errors during subsequent draws.

PT-141 Dosing Calculator: Converting Concentration to Syringe Marks

Once reconstituted, you need to convert your prescribed dose from milligrams or micrograms into a volume you can measure on a syringe.

Understanding Insulin Syringe Units

A standard U-100 insulin syringe has 100 marks per mL. Each mark equals 0.01 mL. On a 1 mL syringe labeled in "units," 10 units equals 0.1 mL and 100 units equals 1.0 mL.

Concentration Reference Table

| BAC Water Added | PT-141 Vial Size | Final Concentration | 1 mg dose volume | 0.5 mg dose volume | |---|---|---|---|---| | 1 mL | 10 mg | 10 mg/mL | 0.1 mL (10 units) | 0.05 mL (5 units) | | 2 mL | 10 mg | 5 mg/mL | 0.2 mL (20 units) | 0.1 mL (10 units) | | 2 mL | 5 mg | 2.5 mg/mL | 0.4 mL (40 units) | 0.2 mL (20 units) |

The 2 mL dilution (5 mg/mL) is generally preferred for starting doses of 0.5 to 1 mg because it puts the dose in a measurable 0.1 to 0.2 mL range on a standard insulin syringe, reducing the chance of over- or under-draw errors.

Dose Guidance From Clinical Trials

In the Phase 3 trials that led to Vyleesi's FDA approval, bremelanotide 1.75 mg subcutaneously was administered as-needed 45 minutes before anticipated sexual activity [6]. The RECONNECT trials (two randomized, double-blind, placebo-controlled studies; combined N = 1,247 premenopausal women) demonstrated a statistically significant increase in satisfying sexual events vs. Placebo at that dose (P<0.001) [6]. For compounded PT-141 used off-label, prescribers commonly start at 0.5 to 1 mg and titrate based on response and tolerability, though formal titration studies at these lower doses are limited.

The FDA label states: "The recommended dose of Vyleesi is 1.75 mg injected subcutaneously in the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity. Limit use to one dose within 24 hours and no more than one dose per day" [1].

Syringe Selection and Injection Technique

Choosing the Right Insulin Syringe

For PT-141, a 1 mL (100-unit) insulin syringe with a 29 to 31 gauge needle is ideal. The 31-gauge needle (0.26 mm diameter) produces the smallest puncture wound and the least injection-site discomfort. Needle length of 5/16 inch (8 mm) or 3/8 inch (9.5 mm) is sufficient for subcutaneous tissue in the abdomen and thigh in most adults, as subcutaneous fat depth typically ranges from 8 to 40 mm depending on body site and adiposity [7].

Avoid 27-gauge or larger needles for routine PT-141 injection. They draw back the solution faster, which sounds convenient, but they also increase local tissue trauma. Reserve larger gauges for the BAC water transfer step only.

Injection Sites

The FDA-approved Vyleesi label designates the abdomen and thigh as the recommended subcutaneous injection sites [1]. Rotate within and between sites to prevent lipohypertrophy at the same spot over time. A 2022 review in Diabetes Technology and Therapeutics confirmed that consistent site rotation reduces subcutaneous tissue damage and absorption variability by up to 23% [8].

Injection Technique

1. Pinch a fold of skin between thumb and forefinger.
2. Insert the needle at a 45-degree angle (or 90 degrees if using a 4 mm pen needle or if body fat is ample).
3. Release the skin fold before depressing the plunger.
4. Inject slowly over 5 seconds.
5. Withdraw the needle at the same angle it entered.
6. Apply light pressure with a clean swab. Do not rub.

Storage After Reconstitution

Reconstituted PT-141 must be refrigerated at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) immediately after preparation. Do not store it in the door shelf of the refrigerator, where temperature fluctuates every time the door opens. Place it on an interior shelf, away from the cooling element to avoid accidental freezing.

Why Freezing Is Harmful

Ice crystal formation during freezing can physically shear peptide chains and alter the three-dimensional structure of bremelanotide. A degraded peptide may still appear clear in solution, so you cannot detect freeze damage visually. Once a reconstituted vial has been frozen, discard it.

Protecting From Light

Keep the vial in its original carton or wrap it in aluminum foil between uses. Ultraviolet light degrades peptide bonds, particularly in melanocortin peptides that contain a His-Phe-Arg-Trp sequence [2]. The lyophilized powder (pre-reconstitution) is stable for 24 months when stored below 25 C and protected from light per standard compounding monograph specifications.

Beyond-Use Dating

USP Chapter 797 specifies that multi-dose sterile preparations compounded using a preservative-containing diluent like BAC water carry a 28-day beyond-use date after first use when stored at 2 to 8 C [4]. Discard any unused solution on day 28 regardless of how much remains.

Safety Profile: What to Expect and What to Watch For

Nausea is the most frequently reported adverse event with bremelanotide. In the RECONNECT Phase 3 trials, nausea occurred in 40% of women receiving bremelanotide 1.75 mg vs. 1% on placebo [6]. Flushing, injection-site bruising, headache, and transient blood pressure increases were also reported.

Transient Blood Pressure Increase

Bremelanotide produces a transient mean decrease in heart rate and a mean increase in systolic blood pressure of approximately 3 to 6 mmHg peaking within 12 minutes of injection, resolving within 12 hours [1]. The FDA label carries a contraindication for patients with known cardiovascular disease or uncontrolled hypertension. Confirm with your prescribing physician that your cardiovascular baseline has been assessed before the first dose.

Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breasts has been reported with repeated bremelanotide use, driven by off-target MC1R stimulation in melanocytes [2]. This effect appears dose-dependent and cumulative. The FDA label recommends discontinuing use if hyperpigmentation occurs [1].

Who Should Not Use PT-141

• Patients with known cardiovascular disease
• Those with uncontrolled hypertension
• Women who are pregnant or trying to conceive (teratogenicity data are insufficient)
• Patients on medications that cause significant QT prolongation
• Those with a history of hypersensitivity to bremelanotide or any melanocortin agonist

Common Reconstitution Errors and How to Avoid Them

Wrong Diluent Volume

Adding 1 mL instead of 2 mL to a 10 mg vial doubles the concentration to 10 mg/mL. A patient drawing 0.1 mL thinking they have 0.5 mg would actually receive 1 mg. Double-check your arithmetic before inserting the needle into the BAC water vial.

Shaking Instead of Swirling

Shaking denatures the peptide and creates a foamy, aerated solution with unreliable concentration per draw. If foam forms, let the vial sit undisturbed for 15 minutes. The foam may settle. If the solution remains cloudy or foamy, discard.

Touching the Needle Tip

Any contact between the needle and a non-sterile surface contaminates the syringe. Use a fresh needle for every injection. Never recap a used needle by hand; use the one-handed scoop technique or a needle-capping device.

Storing at Room Temperature

Peptides degrade faster at room temperature. A study of related melanocortin peptides found measurable degradation within 72 hours at 25 C, compared with stable concentrations over 28 days at 4 C [9]. Refrigerate immediately after every use.

Forgetting to Label

Unlabeled vials get mixed up. Mark every vial with the compound name, concentration, reconstitution date, and beyond-use date before putting it away.

Practical Timing and Use Guidance

The FDA-approved dosing schedule specifies administration at least 45 minutes before anticipated sexual activity. Clinical pharmacokinetic data show that bremelanotide reaches peak plasma concentration (Cmax) at approximately 1 hour post-subcutaneous injection [1]. The half-life is 2.7 hours, meaning the compound is largely cleared within 8 to 10 hours.

For off-label compounded PT-141 starting at lower doses (0.5 mg), the same 45-minute pre-activity window applies based on the shared pharmacokinetic profile. Some clinicians recommend a 60-minute lead time for first-time users to allow assessment of initial tolerability before activity begins.